NSE · LAURUSLABS
Laurus Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,014 Cr with net profit ₹388 Cr — a 19.27% net margin, versus 16.5% the period before.
Shareholding
As of 2026-09-30
- Promoter27.47%
- Public29.83%
- FII30.84%
- DII11.86%
3,11,892 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.71× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #2 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited(this company) | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
AI analysis
AI-generated · google/gemini-2.5-flashLaurus Labs Limited has a market capitalization of Rs 84220 Cr. The company reported a revenue of Rs 6867.85 Cr with a profit margin of 13.05%. Its current PE ratio is 301.53, and the debt-to-equity ratio stands at 0.54. The return on equity is 16.77% and return on capital employed is 16.14%.
Positives
- +Revenue increased by 22.7% to Rs 6867.85 Cr.
- +Return on Equity (ROE) stands at 16.77%.
- +Return on Capital Employed (ROCE) is 16.14%.
- +The dividend yield is 13%.
Negatives
- −The trailing twelve-month PE ratio is 301.53, which is high.
- −Promoter holding decreased from 27.95% in Q4 Mar 2026 to 27.4947% in Q1 Mar 2026.
- −Promoter pledges were 2.69% as of Mar 2026.
Financial Performance
Laurus Labs Limited recorded a total revenue of Rs 6867.85 Cr in the most recent fiscal year, demonstrating a revenue growth of 22.7%. The net profit for the same period was Rs 888.79 Cr. Quarterly revenue for Mar 2026 was Rs 1811.57 Cr, generating a net profit of Rs 279.14 Cr. The company's EPS was 16.56.
Profitability & Returns
The company's profit margin stood at 13.05%. Laurus Labs Limited achieved a return on equity (ROE) of 16.77% and a return on capital employed (ROCE) of 16.14%. The earnings per share (EPS) was Rs 16.56.
Balance Sheet
Laurus Labs Limited has a book value of Rs 98.11. The debt-to-equity ratio is 0.54, indicating its reliance on debt financing relative to equity. The company’s dividend yield is 13%.
Ownership & Pledges
As of Mar 2026, promoter holding in Laurus Labs Limited was 27.4947%. Foreign Institutional Investors (FIIs) held 25.8231%, and Domestic Institutional Investors (DIIs) held 13.9679%. Public shareholding was 32.7143%. A portion of promoter shares, specifically 2.69%, were pledged as of Mar 2026.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.